The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC | Common | 00287Y109 | 859,589 | 11,854,758 | SH | SOLE | 11,418,958 | 0 | 435,800 | ||
| ALKERMES PLC | SHS | G01767105 | 443,353 | 7,647,977 | SH | SOLE | 7,366,107 | 0 | 281,870 | ||
| BIOGEN INC | Common | 09062X103 | 100,036 | 368,645 | SH | SOLE | 368,645 | 0 | 0 | ||
| BIOVERATIV INC | Common | 09075E100 | 119,002 | 1,977,764 | SH | SOLE | 1,693,064 | 0 | 284,700 | ||
| GILEAD SCIENCES INC | Common | 375558103 | 157,139 | 2,220,100 | SH | SOLE | 2,220,100 | 0 | 0 | ||
| PROTHENA CORP PLC | SHS | G72800108 | 616,991 | 11,400,424 | SH | SOLE | 10,230,276 | 0 | 1,170,148 | ||
| THERAVANCE BIOPHARMA INC | Common | G8807B106 | 426,531 | 10,706,180 | SH | SOLE | 9,160,110 | 0 | 1,545,998 | ||